8-K
filed January 8, 2024, 6:59 PM ET
ticker APLS
CIK 0001492422
earnings
confidence high
sentiment positive
materiality 0.80
Apellis reports preliminary Q4 2023 U.S. net product revenue of $138M, full year $366M
Apellis Pharmaceuticals, Inc.
2023-FY EPS reported
-$4.45
revenue$396,591,000
- Q4 2023 U.S. net product revenue ~$138M: SYFOVRE $114M, EMPAVELI $24M.
- Full year 2023 U.S. net product revenue ~$366M: SYFOVRE $275M, EMPAVELI $91M.
- SYFOVRE: ~62,000 doses in Q4, ~160,000 total in 2023; ~95% of GA patients use SYFOVRE.
- EMPAVELI: 97% compliance; >50% existing and >90% new patients use Injector since Oct approval.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Apellis Pharmaceuticals, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue EMPAVELI revenue: Approximately $24 million in preliminary fourth quarter; approximately $91 million in full year 2023.
- Period
- fourth quarter and full year ended December 31, 2023
- Revenue
- EMPAVELI revenue: Approximately $24 million in preliminary fourth quarter; approximately $91 million in full year 2023
- Result
- preliminary results
Exact text from the filing
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced preliminary U.S. net product revenues of approximately $138 million for the fourth quarter and approximately $366 million for the full year 2023 for SYFOVRE ® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration and for EMPAVELI ® (pegcetacoplan) for adults with paroxysmal nocturnal hemoglobinuria (PNH).
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Apellis Pharmaceuticals, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue EMPAVELI revenue: Approximately $24 million in preliminary fourth quarter; approximately $91 million in full year 2023.
- Period
- fourth quarter and full year ended December 31, 2023
- Revenue
- EMPAVELI revenue: Approximately $24 million in preliminary fourth quarter; approximately $91 million in full year 2023
- Result
- preliminary results
Exact text from the filing
Approximately $114 million and $275 million expected in preliminary U.S. net product revenues in the fourth quarter and full year 2023, respectively.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Apellis Pharmaceuticals, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue EMPAVELI revenue: Approximately $24 million in preliminary fourth quarter; approximately $91 million in full year 2023.
- Period
- fourth quarter and full year ended December 31, 2023
- Revenue
- EMPAVELI revenue: Approximately $24 million in preliminary fourth quarter; approximately $91 million in full year 2023
- Result
- preliminary results
Exact text from the filing
Approximately $24 million and $91 million expected in preliminary U.S. net product revenues in the fourth quarter and full year 2023, respectively.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.